Claims for Patent: 9,744,144

Summary for Patent: 9,744,144

Title:	Method of treating cardiovascular events using colchicine concurrently with an antiplatelet agent
Abstract:	Methods of treating and/or preventing a cardiovascular event in a patient, the method comprising orally administering a colchicine to a patient who is receiving concurrent treatment with at least one antiplatelet agent, thereby treating and/or preventing the cardiovascular event in the patient are provided.
Inventor(s):	Mark Nidorf
Assignee:	Murray and Poole Enterprises Ltd
Application Number:	US14/603,049
Patent Claims:	1. A method of treating and/or reducing the risk of a cardiovascular event in a patient, the method comprising: administering a composition comprising an effective amount of (i) colchicine, (ii) a salt of (i), or any combination of (i)-(ii) to a patient who is receiving concurrent treatment with at least one antiplatelet agent, wherein the cardiovascular event is acute coronary syndrome, out-of-hospital cardiac arrest, or noncardioembolic ischemic stroke, and wherein the composition is administered once per day, thereby treating and/or reducing the risk of the cardiovascular event in the patient. 2. The method of claim 1, wherein the patient has a coronary disease. 3. The method of claim 2, wherein the coronary disease is a clinically stable coronary disease. 4. The method of claim 1, wherein the antiplatelet agent is aspirin. 5. The method of claim 1, wherein colchicine is included in an amount of about 0.6 mg. 6. The method of claim 1, wherein colchicine is included in an amount of about 0.5 mg. 7. The method of claim 1, wherein the anti-platelet agent is one or more of an irreversible cyclooxygenase inhibitor, an adenosine diphosphate (ADP) receptor inhibitor, a phosphodiesterase inhibitor, a protease-activated receptor-1 (PAR-1) antagonist, a glycoprotein IIB/IIIA inhibitor, an adenosine reuptake inhibitor, a thromboxane inhibitor, and a thromboxane receptor antagonist. 8. The method of claim 7, wherein: (a) the irreversible cyclooxygenase inhibitor is aspirin and/or triflusal; (b) the ADP receptor inhibitor is clopidogrel, prasugrel, ticagrelor, ticlopidine, or a combination thereof; (c) the phosphodiesterase inhibitor is cilostazol; (d) the PAR-1 antagonist is vorapaxar; (e) the glycoprotein inhibitor is abciximab, eptifibatide, tirofiban, or a combination thereof; (f) the adenosine reuptake inhibitor is dipyridamole; and/or (g) the thromboxane inhibitor is terutroban. 9. The method of claim 1, wherein the composition further comprises a pharmaceutically acceptable carrier, diluent, or excipient. 10. The method of claim 1, further comprising co-administering to the patient a therapeutically effective amount of a second agent for the treatment and/or reduction of risk of the cardiovascular event in the patient. 11. The method of claim 10, wherein the second agent is a colchicine-compatible statin. 12. The method of claim 11, wherein the statin is atorvastatin, fluvastatin, lovastatin, pitavastatin, rosuvastatin, simvastatin, pravastatin, a salt thereof, or any combination thereof. 13. The method of claim 1, wherein the composition is administered orally, topically, parenterally, ophthalmically, intraventricularly, intracranially, intraperitoneally, buccally, rectally, vaginally, intranasally, or by aerosol administration and/or inhalation spray. 14. The method of claim 1, wherein the composition is administered in the form of a tablet, capsule, liquid dose, gel or powder. 15. A method of treating and/or reducing the risk of a cardiovascular event in a patient, the method comprising: administering a composition comprising about 0.6 mg of: (i) colchicine, (ii) a salt of (i), or any combination of (i) and (ii), wherein the patient is receiving concurrent treatment with at east one antiplatelet agent, and wherein the cardiovascular event is acute coronary syndrome, out-of-hospital cardiac arrest, or noncardioembolic ischemic stroke. 16. The method of claim 15, wherein the patient has a coronary disease. 17. The method of claim 16, wherein the coronary disease is a clinically stable coronary disease. 18. The method of claim 15, wherein the anti-platelet agent is one or more of irreversible cyclooxygenase inhibitors, adenosine diphosphate (ADP) receptor inhibitors, phosphodiesterase inhibitors, glycoprotein IIB/IIIA inhibitors, adenosine reuptake inhibitors, thromboxane inhibitors, and thromboxane receptor antagonists.